Toward an optimized strategy of using various airway mucus clearance techniques to treat critically ill COVID-19 patients
Changzhou Key Laboratory of Respiratory Medical Engineering, Institute of Biomedical Engineering and Health Sciences, Changzhou University, Changzhou, 213164, China
*Address correspondence to: Mingzhi Luo, email@example.com; Linhong Deng, firstname.lastname@example.org
Received: 16 May 2020; Accepted: 23 September 2021
Abstract: Coronavirus disease 2019 (COVID-19) caused by acute respiratory syndrome coronavirus 2 (SARS-Cov-2) is still threatening the human life and society throughout the world. For those critically ill patients, mechanical ventilation (MV) is essential to provide life support during treatment. However, both the virus infection and MV disrupt the balance between secretion and elimination of airway mucus and lead to mucus accumulation in the lung. Postmortem examination verified that the lungs in patients died of COVID-19 are indeed filled with sticky mucus, suggesting a great need to improve airway mucus clearance in critically ill COVID-19 patients. Therefore, it may be helpful to comprehensively review the current understanding regarding the changes of biochemical and rheological features of airway mucus associated with the disease, as well as the physiological principles and algorithm to decide airway clearance techniques suitable for the critically ill COVID-19 patients. Based on these considerations, optimized strategies may be developed to eliminate the airway mucus accumulated in the airways of critically ill COVID-19 patients.
Keywords: COVID-19; Airway mucus; Rheology; Mechanical force; Airway clearance techniques
|ACTs:||airway clearance techniques|
|ARDS:||acute respiratory distress syndrome|
|COVID-19:||coronavirus disease 2019|
|EPP:||equal pressure point|
|FRC:||functional residual capacity|
|HFCWO:||high frequency chest wall oscillation|
|Hi-PEP:||high pressure positive expiratory pressure|
|Osc-PEP:||oscillating positive expiratory pressure|
|PEF:||peak expiratory flow|
|PEP:||positive expiratory pressure|
|PIF:||peak inspiration flow|
|SARS-CoV-2:||severe acute respiratory syndrome coronavirus 2|
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is still threatening human health worldwide (Sohrabi et al., 2020). COVID-19 patients usually start with common symptoms such as cough and fever, but within two weeks some of them will become either severely (15%) or critically ill (5%) suffering from acute respiratory distress syndrome (ARDS) and even respiratory failure, and most critically ill COVID-19 patients need mechanical ventilation (MV) to provide respiratory support (Brewster et al., 2020; Cascella et al., 2021; Huang et al., 2020; Wu and McGoogan, 2020; Yam et al., 2003; Yang et al., 2020). Unfortunately, these mechanically ventilated COVID-19 patients are still risk an over 50% fatality rate (Baden and Rubin, 2020; Cao et al., 2020; Murthy et al., 2020; Wang et al., 2020; Xie et al., 2020).
One of the main reasons for this unacceptably high mortality may be the suffocating mucus accumulation in the airways (Chen et al., 2020). Indeed, airway mucus accumulation or even mucus plug has been observed in both proximal bronchi and peripheral small airways in critically ill COVID-19 patients (Liu et al., 2020a; Lu et al., 2021; Xu et al., 2020). In addition, airway mucus accumulation is thought to result in a common feature of lung opacity in severe COVID-19 patients (Dunican et al., 2018) and severe hypoxemic respiratory failure in a significant proportion of COVID-19 patients (Brosnahan et al., 2020; Wu et al., 2020). It has also been suggested that airway mucus accumulation may lead to silent hypoxia, i.e., oxygen deprivation without breathing problems, which is presented as a unique life-threatening feature of COVID-19 (Khan et al., 2021; Liu et al., 2020b). Airway mucus accumulation is generally associated with respiratory viral infection, but is known to be deteriorated by MV, which may be responsible for airway obstruction and loss of pulmonary function in mechanically ventilated critically ill COVID-19 patients (Chen et al., 2019b; Fahy and Dickey, 2010). Therefore, it is very important to properly manage airway mucus accumulation in COVID-19 patients, especially those critically ill and mechanically ventilated patients (Brosnahan et al., 2020; Cook et al., 2020; Saracoglu et al., 2020; Szarpak et al., 2020).
In clinical practice, airway mucus accumulation can be managed by either pharmacological intervention using mucus thinning and expectorant drugs or physical intervention using so-called airway clearance techniques (ACTs) (Balsamo et al., 2010; Belli et al., 2021; Castro et al., 2013; Fan et al., 2017; Gosselink et al., 2008; Poole and Black, 2003; Rogers and Barnes, 2006). In fact, a spectrum of ACTs have been proved effective in helping clearing airway mucus accumulation such as postural drainage, breathing maneuvers, manual hyperinflation and mechanical assistive devices, and some of them have been recommended in several therapy guidelines for COVID-19 patients (Belli et al., 2021; Murthy et al., 2020; Thomas et al., 2020). However, there have been few comprehensive and updated reviews focusing on different ACTs in regards of their working mechanisms and efficacies, which is not helpful to fully understand the pros and cons of different ACTs in treating different cases of airway mucus accumulation and thus prevent optimization of ACTs application in treating critically ill COVID-19 patients (Battaglini et al., 2020; Denehy and Berney, 2006; Lazzeri et al., 2020; Thomas et al., 2020; Vitacca et al., 2020).
Therefore, in this review article we first summarize the changes of biochemical and rheological properties of airway mucus and the correlated risk factors of airway mucus accumulation, especially in COVID-19 patients. Then, we focus on the basic rationales for airway mucus clearance and the associated ACTs that may be suitable for critically ill COVID-19 patients. Based on such deep understanding of airway mucus accumulation and ACTs, an optimized strategy may be established for application of ACTs in management of airway mucus accumulation in critically ill COVID-19 patients (Ambrosino and Clini, 2015; Stiller, 2000).
Airway Mucus Accumulation in COVID-19 Patients
In COVID-19, it has been reported that a large proportion of the patients present symptoms of cough (67.8%) and sputum production (33.7%), both of which are known to be associated with excessive airway mucus secretion (Guan et al., 2020; Wang et al., 2020). These data suggest that airway mucus accumulation may be a common phenomenon in COVID-19, due to a combination of dysfunction of mucociliary clearance (MCC), airway mucus hypersecretion, and changed rheology as described in the following.
Mucociliary clearance in healthy subjects and COVID-19 patients
Airway mucus in healthy subjects usually acts as an essential protective physical barrier by forming a thin layer on top of the airway lumen and then constructing MCC together with cilia (about 200 per cell, 6-7 μm long). Under the cyclic beatings of cilia including a fast effective stroke and a slow recovery stroke (10~15 Hz), the inhaled particles and pathogens can be trapped in the airway mucus and eliminated from the airway system (Fig. 1) (Loreng and Smith, 2017; McAuley et al., 2019; Ridley and Thornton, 2018; Roy et al., 2014; Sanderson and Sleigh, 1981; Widdicombe, 1997; Xu and Jiang, 2019b).
According to its location to cilia, the airway mucus layer can be divided into an apical high viscosity layer (mucus gel, 10-50 μm depth) and a bottom low viscosity layer (periciliary layer, PCL, 7 μm depth) (Button et al., 2012; Thornton and Sheehan, 2004). Since the height of cilia is similar to the depth of PCL layer, most of the movements of cilia occur in the PCL layer. Therefore, during the effective strokes the cilia intermittently sweep the subside of the mucus gel, which leads to the mucus cephalad transport (~100 μm/s) (Silberberg, 1990). This high turnover rate of airway mucus by MCC is a major feature of the respiratory system in healthy subjects. However, in COVID-19 patients, SARS-CoV-2 infection is known to seriously disrupt the function of MCC. For example, it has been reported that SARS-CoV-2 infection inadvertently leads to the shedding of ciliated cells from the airway epithelium (Fang et al., 2020). This is partly because that a subpopulation of the ciliated cells highly express ACE2 and TMPRSS2 and thus mediate the initial infection and cellular entry of SARS-CoV-2 (Chilvers et al., 2001; Lee et al., 2020; Sungnak et al., 2020; Ziegler et al., 2020; Zou et al., 2020). In addition, it has been demonstrated in a reconstituted human bronchial epithelial model that SARS-CoV-2 preferentially replicates in ciliated cells, which causes a rapid loss of the ciliary layer and thus compromises the motile function of the cilia (Brosnahan et al., 2020). On the other hand, the intrinsic epithelial defense mechanisms likely occur too late to prevent such cilia loss due to SARS-CoV-2 infection (Robinot et al., 2020).
Apart from the structural dysfunction of MCC, SARS-CoV-2 also disrupts the cilia beating through interference with the physiologically relevant signaling that modulates the cilia beating frequency, such as ATP, acetylcholine, cyclic adenosine monophosphate, cyclic guanosine monophosphate, nitric oxide, and inositol trisphosphate (Essaidi-Laziosi et al., 2018; Kuek and Lee, 2020). Both the structural and signaling dysfunctions of the airway epithelium and the airway cilia would inevitably reduce the ability of MCC to remove airway mucus from the lung, which partially explains why airway mucus accumulation is so common and severe in critically ill COVID-19 patients.
Airway mucins in healthy subjects and COVID-19 patients
The principal components of airway mucus both structurally and functionally are mucins, and there are at least nine types of them in human airways (Chatterjee et al., 2020; Lillehoj et al., 2013). Among these mucins, MUC1, MUC4 and MUC16 mainly locate in the PCL layer tethered to the plasma membrane of airway epithelium via a transmembrane domain, which attract water, thereby forming a lubricate fluid layer surrounding and protecting the cilia to promote movement of the mucus gel above. The gel-forming MUC2, MUC5A/C, MUC5B and MUC19, and the non-gel forming MUC7 and MUC8 mainly locate in the mucus gel layer after secretion by goblet cells (Fig. 1) (Denneny et al., 2020; Dhanisha et al., 2018; Fahy and Dickey, 2010; Hattrup and Gendler, 2008; Ridley and Thornton, 2018; Thornton et al., 2008).
Airway mucins always contain highly repeated domains of proline, threonine and serine. Since both threonine and serine mediate glycosylation via their oxygen, airway mucins are thus heavily glycosylated (20% protein core and 80% carbohydrates). In addition, the gel-forming mucins also contain abundant cysteine, which mediates the non-covalent and covalent crosslinks between the ends of different mucins due to their hydrophobic property and the disulfide formation, respectively. Consequently, the gel-forming mucins form polymers up to 5 μm long from only 0.2–0.6 μm long mucin monomers (Bansil et al., 1995; Sheehan et al., 1991). Once secreted, these heavily glycosylated long polymeric mucins interact with ions and absorb water and then increase the volume by several hundred times within seconds, forming a three dimensional lattice hydrostatic mucus gel (Quraishi et al., 1998). Therefore, the airway mucus in the gel layer acquires both viscosity and elasticity, a physical property that is characteristic of complex fluids.
Besides their roles in determining airway mucus physical properties, airway mucins also have vital roles in protection of airways from infection by viruses such as SARS-CoV-2. For example, it has been shown that the terminal sialic acid glycans in gel-forming mucins including MUC5AC and MUC5B can facilitate the interaction with coronavirus (Ganesan et al., 2013). Consequently, the airway mucins may act as the primary site to entrap the viral particles and then remove them from the respiratory tract via MCC. The finding that COVID-19 patients have a higher level of MUC5B than their healthy counterparts seems to corroborate the protective role for MUC5B in this disease (Iyer et al., 2020).
In addition, MUC1, MUC4 and MUC16 in the PCL layer (transmembrane mucins) can bind to coronavirus such as SARS-CoV-2 via the interaction of adhesion and sialic acid, which may prevent the entry of virus into the airway cells (Chatterjee et al., 2020; Zou et al., 2020). The transmembrane mucins are also known to shed their extracellular domains from the cell surface into the airway lumen, which is cleavaged by endogenous protease that is activated due to mucin-virus interactions (McAuley et al., 2017). Therefore, transmembrane mucins such as MUC1, MUC4, and MUC16 located on the surface of cilia can act as releasable decoy receptors and prevent the virus infection (Chatterjee et al., 2020).
Hypersecretion of airway mucins in COVID-19 patients
In COVID-19 patients, the expression of airway mucins may be enhanced in response to SARS-CoV-2 infection via several signaling pathways, which leads to airway mucus accumulation (Bose et al., 2021; Khan et al., 2021; Plante et al., 2020). For example, SARS-CoV-2 infection may stimulate differentiation and hyperplasia of the goblet cells in the airways, which is followed by hyperproduction and secretion of mucins. Up to date, enhanced expression of various mucins particularly MUC1, MUC2, and MUC4, MUC5AC, MUC5B, and retention of highly viscous mucus in bronchial airways have been observed in COVID-19 patients (Chen et al., 2020; Leng et al., 2020; Lu et al., 2021; Wang et al., 2020; Ye et al., 2020; Zhang et al., 2021).
One of the causes of airway mucin hypersecretion in COVID-19 is the SARS-CoV-2 induced excessive inflammatory response known as cytokine storm, which is summarized by Castelli et al. (2020) in their review article. Briefly, numerous cytokines facilitate mucin expression via various signaling pathways. Among them, IL-2, IL-4, IL-8, IL-9, IL-13 and IL-19 facilitate mucin expression via activation of STATs signaling, IL-1β, IL-5, IL-6, and IL-19 facilitate mucin expression via activation of MAPK signaling, while EGF, ATP and adenosine facilitate mucin expression via activation of NF-κβ signaling. In addition, it has been reported that SARS-CoV-2 increased IFN-β/γ expression, which enhanced expression of airway mucins such as MUC1, MUC2, MUC5AC, MUC5B, MUC13 and MUC16 via activation of IDO1-AhR axis (Hadjadj et al., 2020; Liu et al., 2020b). Since cytokine storm is a general feature in critically ill COVID-19 patients, these patients are also generally associated with airway mucin hypersecretion (Wang et al., 2020).
The role of airway mucus rheology in COVID-19 patients
Airway mucus is a material that behaves like both a viscous fluid and a soft elastic solid, a rheological feature known as viscoelasticity. This airway mucus rheology can be impacted by virus infection and thus differently modulates the cilia beating and mucus transport.
Changes of airway mucus rheology in COVID-19 patients
In COVID-19 it has been reported that a proportion of the critically ill patients are often seen with highly viscous airway mucus that even forms colloidal mucus plugs in the bronchioles (Wang et al., 2020). The abnormal rheological properties and mucus accumulation/plugging in the COVID-19 patients may result from various factors such as increased content of solids in the airway mucus (up to 15% as reported by (Button et al., 2016) as well as changes in hydration, pH, and ion composition of the airway mucus (Ridley and Thornton, 2018).
The risk of mucus accumulation in critically ill COVID-19 patients
In healthy persons, mucus is continuously secreted into airways with totally about 10–100 mL/day. Under the function of MCC, mucus will move from peripheral airways to the glottis, and then be cleared by swallowing or coughing (Button et al., 2012; Dickey, 2018). For critically ill COVID-19 patients, viral infection and the following inflammatory responses lead to airway mucus accumulation by changing mucus viscoelasticity, stimulating mucus hypersecretion, and disturbing mucus elimination as described above (Button et al., 2016; Ridley and Thornton, 2018; Wang et al., 2020).
Once the sticky airway mucus accumulates in the airways, it provides a favorable growth media for bacteria (Konrad et al., 1994; Li Bassi et al., 2008; Safdar et al., 2005). Bacterial infection will cause airway inflammation, which then induces goblet cells hyperplasia and submucosal gland hypertrophy, and leads to further mucus secretion and thus a vicious cycle of infection, inflammation, and hypersecretion. Additionally, the sticky airway mucus leads to the shedding of ciliated cells and impairs ciliary beating, and thus disrupts the function of MCC. Both the increased secretion of sticky airway mucus and the impaired MCC will further accelerate airway mucus accumulation (Anderson et al., 2015; Zahm et al., 1989).
Airway mucus accumulation can increase airway resistance and thus deteriorate lung function presenting as decreased forced expiratory volume in one second, which will lead to atelectasis, ARDS, ultimately the total obstruction of respiratory tracts and respiratory failure (Cerveri and Brusasco, 2010; Chen et al., 2019b; Curran and Cohn, 2010; Darbee et al., 2005; Dunican et al., 2018; Fahy and Dickey, 2010; Hogg, 2004; Sprung et al., 2010). Therefore, airway mucus accumulation may be one of the causatives for the high death rate of critically ill COVID-19 patients (Chen et al., 2020; Lu et al., 2021; Zhang et al., 2021), and aggressive management of airway mucus accumulation by using appropriate ACTs is essential in clinical practice of treating respiratory conditions including critically ill COVID-19 patients (McKim et al., 2011; Thomas et al., 2020).
The direct impact of rheology on the transport of airway mucus
Airway mucus rheology determines the efficacy of MCC via modulating the mechanical coupling between the cilia and the mucus (Macchione et al., 1995; Quraishi et al., 1998; Rajendran and Banerjee, 2020; Silberberg, 1983). Therefore, a suitable viscoelasticity is required for the airway mucus to facilitate the conversion of energy from the cilia beating into mucus movement. Indeed, it has been widely reported that the airway mucus with an elastic modulus at 1–2 Pa and a zero shear rate viscosity (yield) 12 Pa∙s (0.01 s−1) is most suitable for the function of MCC (Majima et al., 1991; Puchelle et al., 1987; Rubin et al., 1990; Shih et al., 1977). Studies have also shown that the ratio of elasticity to viscosity and the overall impedance rather than viscosity and elasticity alone are more significantly associated with the function of MCC (Lorenzi et al., 1992).
Interestingly, airway mucus can switch between viscous and elastic features depending on the magnitude of external deformation rates (Chen et al., 2019a; Cone, 2009). For example, when it is sheared airway mucus undergoes a process of thinning due to a temporary realignment of mucins (Volsko, 2013). Because of these, several types of mechanical force including gravitational force, friction force, shearing force, and adhesion force may function together to determine the airway mucus rheological features and thus correlate the tendency of mucus movement (Fig. 2). This confers the ability of external mechanical forces due to tidal breathing (0.3 Hz), ciliary beating (10–15 Hz), forced expiratory maneuvers to regulate mucus rheology and the following mucus transport (Branson, 2007; Lai et al., 2009).
Based on the rheological response of airway mucus to different external forces, it is possible to develop a variety of ACTs for clinical usage. For example, gravity, oscillation, and inspiration/expiration flow have been utilized to modulate airway mucus transport. Indeed, using in vitro and in vivo models, it has been reported that oscillation of mucus can decrease its viscoelasticity in a time, frequency, and magnitude-dependent manner. Interestingly, the oscillation to reduce mucus viscoelasticity is found to be most potent at 12–15 Hz, which is similar to the cilia beating frequency (App et al., 1998). Therefore, oscillation-based working mechanisms have been developed and integrated into different types of ACTs (Huang et al., 2020; Rogers, 2007; Zhu et al., 2020).
Basic Rationales for Clearance of Mucus from Obstructed Airways
Current methodologies for clearance of mucus-obstructed airways are all based on utilizing different physiological processes to effectively eliminate airway mucus, such as ventilating behind the obstructed airways/alveoli, increasing expiratory flow rate/flow bias, enhancing the beating of the cilia and decreasing the viscosity of airway mucus (Ambrosino and Clini, 2015; Denehy and Berney, 2006; Kim, 1997; Lester and Flume, 2009; McCarren and Alison, 2006; Pathmanathan et al., 2015; Rogers and Doull, 2005). The basic rationales for these methods are discussed in detail as below.
Ventilating behind the obstructed airways/alveoli
If mucus obstructs the airways/alveoli, ventilating behind the obstructed regions is helpful to push the retained airway mucus out, which can be realized via interdependence of the adjacent alveoli and the collateral channels as shown in Fig. 3 (Cetti et al., 2006; Terry and Traystman, 2016).
For obstructed alveoli that are adjacent and physically interconnected, the expansion of alveoli exerts traction forces and opens adjacent collapsed alveoli, thereby assisting ventilation to these regions, which is called interdependence of adjacent alveoli (McIlwaine et al., 2017).
For obstructed airways especially the peripheral small airways, ventilation can be realized through some collateral channels that connect from either bronchioles to bronchioles (channels of Martin), bronchioles to alveoli (channels of Lambert) or alveoli to alveoli (pores of Kohn, ~50/alveolus). Once the airways are obstructed, these collateral channels can assist ventilation behind the obstructed regions to promote clearing the airway mucus since airflow prefers the path of least resistance (Slebos and Shah, 2017).
Ventilation through these accessory pathways can be generated by holding breath, increasing inspiratory flow rate/volume, and increasing positive pressure, which forms the basis of several ACTs such as breathing maneuvers, hyperinflation, and positive expiratory pressure (PEP) (Branson, 2007). In addition to ventilation behind the obstructed airways/alveoli, there are several other ways to physically enhance the fluidity and thus clearance of airway mucus that are discussed respectively in the following.
Increasing expiratory flow
Expiratory airflow especially peak expiratory flow (PEF) provides shearing forces on airway mucus surface to mobilize its cephalad movement via a two-phase gas-liquid flow mechanism (Fig. 4) (Kim et al., 1986a; Kim et al., 1987; Kim et al., 1986b; Leith, 1968). Basically, once the shearing force exceeds the surface tension and the adhesive force of the mucus gel layer, the airway mucus starts to flow concurrently with the expiratory airflow in a pattern dependent on the magnitude of PEF, i.e., the expiratory air flows as either 1) fine bubbles in the airway mucus (bubble flow) for PEF <18 L/min; 2) large plugs in the airway mucus (plug flow) for PEF at 18-300 L/min; 3) a core inside an annulus of airway mucus (annular flow) for PEF at 300–750 L/min; or 4) fine drops combined with airway mucus (mist flow) for PEF >750 L/min. Among them, both the annular and mist flows can initiate cephalad movement of retained airway mucus (Kim et al., 1986a; Kim et al., 1987; Kim et al., 1986b; Leith, 1968).
It is generally known that PEF is proportional to the intrapulmonary pressure and inversely proportional to the airway resistance. Therefore, increasing the intrapulmonary pressure and decreasing the airway resistance have been used to increase PEF for airway mucus clearance in various ACTs (Maxwell and Ellis, 1998). For example, spontaneous forced expiration maneuvers such as cough and huff, mechanical device assistance such as mechanical insufflation-exsufflation (MI-E) can be used to generate increased intrapulmonary pressure. In addition, according to Poiseuille’s law the airway resistance (R) is proportional to the length (l) and inversely proportional to the 4th power of radius (r) of the airways tract, as well as proportional to the viscosity (η) of air and the airway mucus (R = 8ηl/πr4). Therefore, the airway resistance can be decreased by either increasing airway radius via hyperinflation or decreasing the viscosity of the airway mucus via shearing-thinning by cough, huff, and MI-E (Kim et al., 1987).
On the other hand, the intrapulmonary pressure during forced expiratory will gradually decrease from the alveoli to the mouth because of frictional pressure loss, and there will be a point where the intrapulmonary pressure equals to the surrounding pleural pressure (i.e., equal pressure point, EPP) (Oberwaldner, 2000). From the EPP toward the mouth in the downstream, the pleural pressure exceeds the intrapulmonary pressure and airway compression occurs, which narrows the airway transiently and thus increases PEF and favors a cephalad mucus flow according to Bernoulli’s principle (Fig. 5) (Hollandl and Buttonl, 2006; Kaminsky and Chapman, 2020; van der Schans, 2007).
The location of EPP is mainly determined by the expiratory force and the elastic recoil of the lung, which usually occurs in the central airways. This is why cough and huff are usually effective for clearing airway mucus in the central airways especially above the sixth or seventh generations of airway branching (Button and Button, 2013; Oberwaldner, 2000). However, increasing expiratory force and elastic recoil can shift the site of EPP toward the alveoli, which provides the rationale for ACTs to clear airway mucus in small airways and alveoli by using enhanced force expiratory flow, PEP, and high frequency chest wall oscillation (HFCWO). Since the elastic recoil of the lung is also determined by the lung volume, it is another rationale for ACTs to remove mucus from the distal and central airways by using low and high lung volumes, respectively (Fink, 2007).
Increasing cephalad-bias flow
In addition to increasing expiratory flow, the flow bias between inspiratory and expiratory flows also influences the cephalad transport of airway mucus (Maxwell and Ellis, 1998; McIlwaine et al., 2017; Volpe et al., 2020). This is due to the fact that although the volume of air moving in and out of the airways during inspiration and expiration is equal, the peak flow during inspiration (PIF) is always different from that during expiration (PEF).
Early studies proposed the flow bias threshold for initiating a cephalad mucus movement in terms of PEF/PIF ratio > 1.1 (Kim et al., 1987). Later study, however, demonstrated that it is the difference between PEF and PIF rather than the PEF/PIF ratio that determines the airway mucus mobilization (Volpe et al., 2008). Although PEF-PIF >17 L/min is the normal threshold for initiating cephalad mucus movement, PEF-PIF >33 L/min is observed in vivo as a threshold to initiate mucus movement in mechanically ventilated patients and this threshold is probably more clinically relevant (Li Bassi et al., 2012). Recently, it has been updated to include three criteria for an expiratory flow bias to mobilize airway mucus cephalad movement, i.e., PEF/PIF ratio > 1.1, PEF-PIF > 17 L/min, PEF/PIF ratio > 4.3 and PEF-PIF > 33 L/min (Oliveira et al., 2019b; Volpe et al., 2008). It is worth emphasizing that this rationale does not depend on a high flow rate and can be applied even under tidal volume ventilation.
Oscillating intrapulmonary airflow
Oscillating intrapulmonary airflow can enhance mucus clearance by increasing the rate and bias of expiratory flow, ciliary beat frequency, or mucus hydration as well as by altering the rheological properties of mucus, which can occur in both the central and the peripheral airways (Boucher, 2002; Dasgupta et al., 1998; Hansen et al., 1994; King et al., 1983; Puchelle et al., 1995; Winters et al., 2007; Winters and Yeates, 1997).
The oscillation of intrapulmonary airflow can be induced by either directly oscillating the airflow at the mouth with an oscillatory positive expiratory pressure (Osc-PEP) or vibrating the thorax using HFCWO, both of which have been proved sufficient to overcome the mucus adhesion to the airway wall in the central and peripheral airways and consequently propel the mucus up and out of the airway (Button et al., 2007; Dietl et al., 2001; Tarran et al., 2005).
Physically thinning airway mucus
As mentioned above, shear stress can physically thin airway mucus, which is also an essential pathway to promote mucus clearance (Shen et al., 2018). Apart from shear stress, nanoparticles can also be used to physically thin airway mucus. For example, it has been reported that Fe2O3 nanoparticles (rod-shape, 8 nm diameter, 100 nm length) can experimentally induce physical thinning of simulated asthmatic airway mucus (Fig. 6), which may be mediated by the surface interaction between the Fe2O3 nanoparticles and the mucin polymers (Wang et al., 2017). Our preliminary data also showed that magnetic field-driven movement of Fe2O3 can further decrease the viscoelasticity of the stimulated asthmatic airway mucus (data not shown). Since nanoparticles can be easily delivered into the central and peripheral airways, the phenomenon of mucus thinning induced by Fe2O3 nanoparticles provides another rationale for ACTs to physically thin the airway mucus and thus enhance the removal of mucus from the airways. These results suggest that novel nanotechnologies may provide alternative options for modulating airway mucus rheology for the purpose of promoting efficiency of ACTs.
Airway Clearance Techniques
Based on the above described rationales of mucus clearance, a variety of ACTs have been developed and applied in clinics including postural drainage, breathing maneuvers, conventional manual chest physiotherapy (percussion and vibration), airway oscillating PEP devices, external high-frequency chest oscillating devices, simulating cough devices such as manual hyperinflation (MHI), ventilator hyperinflation (VHI), and MI-E, as well as tracheal suctioning (Table S1).
Postural drainage is an ACT that uses different body positions such as upright, side-lying, supine and prone to directly enhance airway mucus movement from the five lobes of the lung (Berney et al., 2012; Button and Button, 2013; Li Bassi et al., 2008; Safdar et al., 2005). These precise postures comprehensively utilize the anatomy of the bronchial tree, and thus facilitate the sliding of airway mucus from the periphery toward the central airways and improve ventilation and perfusion via gravity-dependent strategies. Among them, the prone position is most effective and has been strongly recommended for mechanically ventilated COVID-19 patients, because it promotes drainage of airway secretion, homogenizes lung perfusion, and improves ventilation mismatch (Gattinoni et al., 2020). It is also reported that although machine vibration or manual clapping does not affect severe-to-critical progression of COVID-19 patients, the prone position has been proved effective to avoid this progression via promoting mucus drainage (Wang et al., 2020).
Various breathing maneuvers are known to be used as helpful ACTs to clear sticky mucus out of the obstructed regions, including 3-second breath holdings, thoracic expansion exercises, mobilization by increasing expiratory flow rate or volumes, forced expiration, active cycle of breathing, and autogenic drainage (Lewis et al., 2012).
Each of these maneuvers works differently to promote mucus clearance. Specifically, the 3-second breath holdings can increase the constant time that allows the air to flow to the obstructed regions of the lung via accessory pathways as described before (Maxwell and Ellis, 1998; McIlwaine et al., 2017). The thoracic expansion exercises use a deep, slow inspiration to increase the lung volume and thus promote ventilation to the obstructed airways via accessory pathways. Mobilization increases oxygen demand and thus increases the lung volume, which leads to ventilation behind the obstructed regions via accessory pathways (Amidei, 2012; Hodgson et al., 2014; Thomas, 2013a, b). Forced expiration such as cough and huff relies on an adequate expiratory flow rate and volume to clear the airway mucus. The active cycle of breathing combines breath holding, deep inspiration and forced expiration (Bott et al., 2009). This maneuver consists of one or two forced expirations followed by relaxed breathing. Autogenic drainage uses gently accelerated tidal volume breathing and gradually increased lung volumes to increase the expiratory flow rate and thus improve mucus clearance from peripheral to central airways (Maxwell and Ellis, 1998; McIlwaine et al., 2017). It needs to note that these breathing maneuvers may not be practical for critically ill COVID-19 patients because of their severe infirmity.
Percussion and vibration
Percussion is performed with cupped hands to clap on the thorax of the patients to generate a transient oscillation with a frequency of 3–6 Hz. Such oscillation transmits through the airways to dislodge the airway mucus from the airway wall so that the mucus can be removed out of the airways.
Similarly, the chest wall can be compressed either manually or using mechanical devices such as HFCWO to generate a transient oscillation and compression with a frequency of 3–17 Hz (McCarren et al., 2006b). This vibration is proposed to remove mucus by increasing PEF (about 50%) and the expiratory flow bias or by decreasing the viscosity of mucus (Kim et al., 1987; McCarren and Alison, 2006; McCarren et al., 2006a). In addition, HFCWO utilizes an inflatable vest that is inflated with an oscillatory pressure below 25 cmH2O at 5–25 Hz. This oscillation pressure can vibrate the chest wall and generate oscillatory airflow to clear airway mucus (Darbee et al., 2005; Kendrick, 2007).
Positive expiratory pressure (PEP)
PEP helps to increase functional residual capacity and thus the tidal volume which can open obstructed airways via accessory pathways and support the airways during expiration to avoid small airway collapse (Branson, 2007; McIlwaine et al., 2015). The patients need to exhale against an expiratory resistor for 8-10 cycles with moderately increased tidal breathing to finally achieve a positive pressure of 10–25 cmH2O (Demchuk and Chatburn, 2021).
Apart from 10–25 cmH2O, PEP can also function with either 40–140 cmH2O high pressure (Hi-PEP), oscillation (Osc-PEP), or ≤1 cmH2O temporary PEP (T-PEP) (Figueiredo et al., 2012). Evidence suggests that Hi-PEP helps to clear airway mucus by ventilating obstructed airways via collateral channels (Clini, 2009; Volsko et al., 2003). It is especially suitable for patients who have an airway instability during forced expiration since it avoids the premature collapse of the airways and thus allows them to exhale a greater volume than the usual forced vital capacity. Osc-PEP is characterized by breathing against intermittent expiratory resistance to induce oscillation of variable frequency and can directly dislodge the sticky mucus and also decrease mucus viscoelasticity in a frequency- and amplitude-dependent manner. T-PEP applies an expiratory pressure at ≤1 cmH2O only for a fraction of the expiratory phase. This increase in low pressure is created through a pulsatile flow at approximately 42 Hz in frequency. The vibration generated by the pulsatile flow is transmitted throughout the airways to detach the mucus. Analysis suggested that T-PEP provides greater benefit to patients with emphysema or on oxygen therapy, while PEP therapy would be of more benefit for patients on mechanical ventilation (D’Abrosca et al., 2017; Nicolini et al., 2018).
Intrapulmonary percussive ventilation
Intrapulmonary percussive ventilation (IPV) provides originally high-frequency mini bursts of air at a rate of 4–10 Hz, which creates an internal vibration in the lung and thus promotes mucus clearance. IPV is recommended for weak and fatigued patients with ineffective cough to loose secretions, which is feasible and safe in spontaneously breathing and non-intubated subjects in critical care (Berlinski, 2019; Hassan et al., 2020). Additionally, IPV can be superimposed on conventional ventilation. The potential benefits of the concomitant use of IPV with ventilation include secretion clearance, improved oxygenation, and intermittent use (Dellamonica et al., 2008).
Lung hyperinflation clears airway mucus by increasing inspiratory flow volume. This will recruit collapsed airways, reduce inspiratory resistance, and thus generate high expiratory flow rate bias and induce annular flow to remove airway mucus, which is predominantly used to move airway mucus from the peripheral airway to the tracheal for mechanically ventilated patients (Savian et al., 2006).
It starts with a slow deep inspiration flow to deliver a high tidal volume up to a peak pressure of 40 cmH2O, and follows by a 3-second breath holding, and then a fast uninterrupted expiratory flow that mimics a forced expiration (i.e., cough) (Berney and Denehy, 2002; Hodgson et al., 2007). This deep inspiration will increase tidal volume by 50% and increase peak intrabronchial pressure to 40 cmH2O (Haake et al., 1987).
Such lung hyperinflation can be realized either manually, i.e., manual hyperinflation (MHI) or mechanically by a ventilator, i.e., ventilator hyperinflation (VHI). For mechanically ventilated COVID-19 patients, VHI is more suitable than MHI, since the patients are already connected to the ventilator and maintained with PEEP, and the outcome of VHI is more reproducible than that of MHI (Haake et al., 1987; Volpe et al., 2020). Furthermore, it has been clarified that among different modes of VHI, the volume-controlled ventilation with inspiratory flow of 20 L/min and pressure support achieves the best effect to remove airway mucus (Ribeiro et al., 2019).
Expiratory rib cage compression
Expiratory rib cage compression (ERCC), also known as manual chest compression, is one of the most commonly used ACTs in ventilated patients (Volpe et al., 2020). ERCC is usually applied either to assist secretion clearance from peripheral to central airways, or to remove secretion from central airways. Unlike the previously described percussion and vibration, ERRC is applied with a steady force that gradually increases from gentle to strong intensity to prolong exhalation after the onset of the expiratory phase, which is used to remove the secretions from distal airways. To remove the secretions from proximal airways, ERRC is applied with hard compression to increase PEF and synchronized with the onset of expiration (Borges et al., 2017; Guimaraes et al., 2013; Martí et al., 2013).
Positive end-expiratory pressure-zero end expiratory pressure
Positive end-expiratory pressure-zero end expiratory pressure (PEEP-ZEEP) consists of increasing PEEP to 15 cmH2O during 5 cycles with peak inspiratory pressure limited to 40 cmH2O, followed by an abrupt reduction of PEEP to 0 cmH2O. By increasing the pressure change at the onset of the expiratory phase, this technique increases the PEF and, consequently, the expiratory flow bias, especially in the volume controlled mode (Amaral et al., 2020; Oliveira et al., 2019a; Volpe et al., 2020). Although both ERCC and PEEP-ZEEP are responsible for increasing the expiratory flow bias, the latter is more potent in this aspect (7 L/min vs. 49 L/min) (Oliveira et al., 2019a).
Mechanical insufflation-exsufflation (MI-E) is the most recently developed technique for mechanically ventilated patients, which delivers a positive inspiratory pressure to the patient to generate a deep inspiration (insufflation) and immediately (10 ms) followed by a negative expiratory pressure generating a deep expiration (exsufflation). In this way, a PEF greater than that induced by coughing can be achieved to remove airway mucus more effectively. In addition, the rapid switch from positive to negative pressure stimulates the bias flow. The advantage of MI-E is that it induces negative pressure throughout central and peripheral airways, suggesting that airway mucus in all generations of the airways can be removed (Ferreira de Camillis et al., 2018; Terzi et al., 2018).
Tracheal suctioning can clear sticky mucus from the trachea and the lower airways, which can be performed via an in-line closed system or an open system (Dodek et al., 2004). Although tracheal suctioning should not be used as a routine ACT for non-intubated patients, it is recommended for the mechanically ventilated COVID-19 patients with suction catheters of an in-line closed system, considering the risk of generating virus aerosol with an open system.
Airway Clearance Algorithm
Although various ACTs can effectively remove airway mucus, there is still no gold standard of clinical ACT practice for critically ill COVID-19 patients. One of the reasons is that one ACT may function differently to different patients depending on the specific pathological process and respiratory mechanics of each individual. Additionally, it may not be possible to compare all the ACTs and affirm the one with superiority. Lastly, each of the critically ill COVID-19 patients can present different respiratory conditions at a different stage of the disease, and thus may need different ACTs over the course of treatment (Battaglini et al., 2020; Lazzeri et al., 2020).
Nevertheless, for critically ill COVID-19 patients, passive ACTs such as postural drainage, percussion, vibration, oscillation, hyperinflation and MI-E may be more suitable than active ACTs such as breathing maneuvers and PEP, because of their physical frailty (Homnick, 2007; van der Schans et al., 1999; Wilson et al., 2019). In addition, the carers in close range of critically ill COVID-19 patients may be endangered by exposure to the virus aerosolized into the environment (Patel et al., 2020; Zayas et al., 2005). Considering this risk, mechanical devices such as HFCWO, VHI, and MI-E are more suitable than manual techniques to be used for the management of airway mucus of critically ill COVID-19 patients, despite that the manual techniques are also effective in mucus clearance. In practice, the treatment approach should be decided based on carefully evaluating the conditions of the patient and the features of available ACTs following the algorithm as shown in Fig. 7 (Chatburn, 2007; Konrad et al., 1994; Sivasothy et al., 2001).
Furthermore, it has been recommended to consider different internal rationales and application conditions of all the ACTs, and thus adapt a combinational therapeutic strategy of using several ACTs during the management of airway mucus (Ramos et al., 2015). For example, although HFCWO is effective to mobilize secretions from the small airways, it does not provide ventilation behind obstructed airways. As a consequence, HFCWO can lead to 10%–50% reduction of the end-expiratory volume, which may close small airways and worsen pulmonary function (Dosman et al., 2003; Jones et al., 1995). However, this event can be avoided by 3-second breathing holds or deep inspiration prior to HFCWO. In addition, HFCWO can be used to mobilize mucus from the small airway to the proximal airways, and then tracheal suctioning can be further used to clear them out from the proximal airway. And when tracheal suctioning does not provide adequate mucus clearance in mechanically ventilated patients, it can be augmented by PEEP-DEEP and MI-E. Compared to tracheal suctioning that is routinely performed for invasive ventilation, MI-E may be more suitable for eliminating airway mucus in ventilated COVID-19 patients due to its advantages in convenience and comfortability in use (Garstang et al., 2000; Sancho et al., 2003). In fact, MI-E is recommended by the Canadian Thoracic Society to be added to or replace the tracheal suctioning (McKim et al., 2011).
Therefore, for critically ill COVID-19 patients, some ACTs such as HFCWO, MHI combined with 3-second breathing hold or IPV may be used together to dislodge the mucus in smaller airways and subsequently move the mucus to the larger airways. Then other ACTs such as tracheal suctioning and/or MI-E should be used to clear these mobilized secretions (Stiller, 2000, 2013; Volsko, 2013).
Limitations of Current ACTs and Future Directions
So far, the underlying mechanisms of airway mucus accumulation in COVID-19 are still unclear, which includes but is not limited to the unknown changes of hydration, biochemical constituents and correlated rheological features in the airway mucus of the patients. The other limitation is that although various ACTs have been used for critically ill COVID-19 patients, there are still not established criteria for determining what ACTs are the most suitable and when they should be used because there is not sufficient evidence to compare and evaluate the currently available ACTs for their efficacy and safety in clinical usage. Therefore, it is urgent for future studies to clarify the changes of specific types of mucins and the correlated rheological properties of airway mucus in COVID-19 patients. It is also necessary to explore new techniques such as abdominal electrical stimulation, nanotechnology, and artificial intelligence for their potential applications in airway mucus clearance, which may be key to optimize the use of existing ACTs as well as develop new ACTs for ultimate control of airway mucus clearance in COVID-19 (Spinou, 2018; Volpe et al., 2020).
COVID-19 is an emerging infectious respiratory disease that has not been completely delineated, and clearance of excessive mucus accumulation in the airways remains one of the biggest challenges in the treatment of critically ill COVID-19 patients due to lack of knowledge of the mucus changes in the disease and corresponding techniques for optimal mucus clearance. In this review, we outline the chemical and rheological features of airway mucus in physiopathological conditions especially in relation to COVID-19 and the currently available ACTs, as well as highlight the essential roles of mechanical forces and their interactions with airway mucus. A clear understanding of these aspects will provide novel insights for new therapeutic approaches or strategies for the airway mucus management of critically ill COVID-19 patients. Based on comprehensive considerations of all these principles and factors, an optimized strategy may be developed to meet the specific requirements for clearing airway mucus in critically ill COVID-19 patients.
Author Contributions: M. Luo and L. Deng conceived and designed the study. M. Luo wrote the manuscript. K. Ni, Y. Sun, J. Guo, and K. Wen collected some data for this manuscript. L. Deng revised the manuscript.
Funding Statement: This work was partially supported by the Key Program of the NSF of China [No. 11532003], the NSF of China [Nos. 12072048, 31670950], the Science and Technology Innovation Leading Plan of High Tech Industry in Hunan Province [2020SK2018], and the Applied Basic Research Project of Changzhou [No. CJ20179039].
Conflicts of Interest: The authors declare that they have no conflicts of interest to report regarding the present study.
|This work is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.|